| Literature DB >> 34098187 |
Laurence Weinberg1, Akshay Hungenahally2, Joshua Meyerov2, Lachlan Fraser Miles3, Daniel Robert Anthony Cox4, Vijayaragavan Muralidharan4.
Abstract
INTRODUCTION: Cerebellar ataxia, neuropathy and vestibular areflexia syndrome (CANVAS) is a rare multisystem neurodegenerative disorder. We describe our perioperative evaluation and care of a patient with CANVAS undergoing a pancreaticoduodenectomy for an ampullary adenocarcinoma, with a focus on perioperative risk stratification and optimisation, intraoperative advanced haemodynamic monitoring and the postoperative care. CASEEntities:
Keywords: Anaesthesia; CANVAS; Case report haemodynamics; Neurological disease; Risk stratification
Year: 2021 PMID: 34098187 PMCID: PMC8187836 DOI: 10.1016/j.ijscr.2021.106058
Source DB: PubMed Journal: Int J Surg Case Rep ISSN: 2210-2612
Fig. 1Intraoperative patient-specific, surgery-specific individualised haemodynamic algorithm.
Fig. 2Intraoperative haemodynamic data (MAP: mean arterial pressure; CI: cardiac index; SVR: systemic vascular resistance; SV: stroke volume; HR: heart rate; SVV: stroke volume variation). Green shaded areas represent haemodynamic “target zones”.
Diagnostic criteria for CANVAS (modified from Szmulewicz et al.) [3].
| Cerebellar ataxia | Neuropathy | Vestibular areflexia | |
|---|---|---|---|
| Possible CANVAS | Cerebellar hypofunction established at bedside, with bedside signs such as FTN ataxia, or dysarthria Does not include down-beating nystagmus because it is too common Cerebellar atrophy on MRI alone is not enough (as this is common in people who partake of ETOH to excess) Exclude: known genetic ataxias (e.g., SCA3, FRDA and SCA7) | Sensory complaints consistent with a sensory deficit, with little motor component Exclude other common sources of sensory syndromes (e.g., diabetes, pyridoxine overdose, Sjogren's syndrome) | Lateral canal type vestibular hypofunction Exclusion of other causes of bilateral vestibular loss (e.g., gentamicin ototoxicity, amiodarone medication) VA established with subjective bedside tests such as HIT or DIE tests |
| Probable CANVAS | Cerebellar atrophy on MRI in addition to cerebellar signs in limbs | Severely abnormal VOR based on objective testing | Neurophysiologic evidence of a sensory ganglionopathy (i.e., requires sensory NCV testing) |
| Definite CANVAS (i.e., autopsy or new genetic test) | Cerebellar atrophy mainly anterior and dorsal vermis and cerebellar loss of Purkinje cells | Vestibular ganglionopathy in temporal bone autopsy | Severe dorsal root ganglion neuron loss on spinal cord autopsy |
| Or a positive genetic test | |||
Anaesthesia considerations and implications for patients with CANVAS.
| Parameter | Concern | Management considerations |
|---|---|---|
| Preoperative | ||
| Patient eligibility for surgery | Goals of surgery Fitness for surgery Patient comorbidities Functional status Frailty Perioperative risk stratification | History, physical examination and investigations Frailty scoring Duke Activity Status Index Nutritional and body composition assessment Multidisciplinary discussion including surgeon, anaesthetist, neurologist, respiratory physician, intensivist, physiotherapist, dietician |
| Preoperative assessment | Dysautonomia Sleep-disordered breathing Cardiac status Upper airway obstruction Respiratory dysfunction Polypharmacy Thermal dysregulation Nutritional risk assessment | Autonomic function assessment (i.e., postural blood pressure test) Screening tool (i.e., STOP-BANG questionnaire) Polysomnography Cardiac function testing (i.e., echocardiography, dynamic stress evaluation) Cardiopulmonary exercise stress test Airway assessment (e.g., Mallampati score) Respiratory function testing Blood gas analysis Medication review |
| Nutritional assessment | Prone to severe nutritional risk defined as: Weight loss >10–15% within six months BMI < 18.5 kg/m2 Nutritional risk assessment score > 5 Serum albumin <30 g/L (with no evidence of hepatic or renal dysfunction) | Nutritional interventional plan Avoid prolonged preoperative fasting Consider carbohydrate drink with 800 ml the night before and 400 ml 2 h before surgery Allow unlimited clear fluids until 2 h before surgery |
| Perioperative | ||
| Positioning | Prone to pressure injuries | Additional gel supports for all joints, cottonwool padding for sacrum and buttocks |
| Anaesthetic technique | Patient non-cooperation, involuntary movements, dystonia, rigidity Cardiorespiratory complications of general anaesthesia | Consider combined regional–general anaesthetic technique |
| Anaesthetic agent | Increased sensitivity to depolarising and non-depolarising agents Perioperative opioid toxicity | Avoid depolarising agents (i.e., succinylcholine) Use non-depolarising agents with caution Avoid opioids and consider multimodal or regional techniques |
| Cardiovascular | Intraoperative hypotension Labile haemodynamic response to fluid shifts and anaesthesia Supine hypertension Labile haemodynamic response to fluid shifts and anaesthesia | Preoperative hydration Advanced perioperative haemodynamic monitoring to guide appropriate fluid and vasopressor support |
| Respiratory | Upper airway obstruction Central respiratory failure | Endotracheal intubation Tracheostomy kit on standby |
| Gastrointestinal | Risk of aspiration | Rapid sequence induction Endotracheal intubation |
| Neurological | Cognitive impairment | Appropriate and targeted communication, support and interaction |
| Thermoregulation | Hyperthermia Hypothermia | Strict control of theatre temperature Patient temperature monitoring |
| Postoperative | ||
| Intensive care support | Complex multisystem management | Individualised postoperative care and support |
| Analgesia | Postoperative opioid toxicity | Cautious use of opioids |
| Haemodynamic management | Postoperative hypotension and autonomic dysregulation Supine hypertension Labile haemodynamic response to fluid shifts | Advanced perioperative haemodynamic monitoring to guide appropriate fluid and vasopressor support |
| Complications | Immobility Haemodynamic instability | Aggressive physiotherapy and mobilisation Early detection and management |
| Nutritional support | Exacerbated stress-related catabolism Impaired metabolic regulation | Integration of nutrition into the overall management of the patient Re-establishment of enteral feeding as early as possible Metabolic control (e.g., of blood glucose) Reduction of factors that exacerbate stress-related catabolism or impair gastrointestinal function Minimise paralytic agents for ventilator-dependent patients Early mobilisation to facilitate protein synthesis and muscle function |
| Psychosocial support | Risk of postoperative depression and anxiety | Early identification and involvement of family, carers and relatives Early involvement of social worker, psychologist or psychiatrist |
Patient laboratory and haemodynamic parameters preoperatively, intraoperatively, and postoperatively (POD: postoperative day).
| Parameter | Presenting bloods | Day 14 post-stenting | Intraoperatively | Intensive care | Discharge | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Tumour removal | Wound closure | Arrival | POD 1 | POD 3 | POD 6 | POD 12 | |||
| Arterial blood gas | Venous | |||||||||
| FiO2 | – | – | 0.6 | 0.3 | 0.7 | 0.7 | 0.4 | 0.4 | 0.28 | Room air |
| pH | – | – | 7.35 | 7.30 | 7.34 | 7.27 | 7.35 | 7.46 | 7.43 | – |
| PaO2 (mmHg) | – | – | 221 | 115 | 210 | 222 | 174 | 102 | 120 | – |
| PaCO2 (mmHg) | – | – | 46 | 51 | 38 | 49 | 41.9 | 37.3 | 35.1 | – |
| Sodium (mmol/L) | 144 | 142 | 139 | 145 | 146 | 147 | 148 | 144 | 142 | 145 |
| Potassium (mmol/L) | 4.6 | 4.3 | 3.7 | 4.5 | 4.3 | 4.2 | 3.8 | 4.8 | 4.3 | 3.9 |
| Chloride (mmol/L) | 105 | 105 | 107 | 108 | 109 | 110 | 107 | 108 | 106 | 104 |
| Bicarbonate (mmol/L) | 28 | 29 | – | 25.2 | 21.6 | 22.5 | 23.1 | 26.9 | 25.8 | 25.7 |
| Base excess (mEq/L) | – | – | 0.3 | −0.8 | −4.5 | −2.9 | −2.1 | 2.8 | 1.6 | 2.7 |
| Lactate (mmol/L) | – | – | 0.8 | 0.8 | 1.5 | 1.8 | 1.5 | 3.2 | 1.9 | 1.4 |
| Haemoglobin (g/dL) | 136 | 134 | 118 | 124 | 129 | 115 | 116 | 110 | 92 | 93 |
| Glucose (mmol/L) | 6.2 | 5.9 | 5.8 | 7.3 | 8.1 | 6.4 | 9.1 | 8.6 | 7.7 | 8.1 |
| Fluid management and vasoactive infusions | ||||||||||
| Fluid balance (mL) | – | – | +350 | +1249 | +1100 | −1285 | +540 | |||
| Balanced crystalloid (mL) | – | – | 650 | 1300 | 1250 | – | – | |||
| Colloid (mL) | – | – | Albumin 20% 200 mL | – | – | – | – | |||
| Oral fluids (mL) | – | – | – | 260 | 350 | – | – | |||
| Noradrenalin (ug/min) | – | – | 2 | 7 | 8 | 8 | 7 | 3 | – | – |
| Weight (kg) | 50.1 | 50.2 | – | – | – | – | 53.5 | 55.9 | 54.5 | 52.7 |
| Frusemide (mg) | – | – | – | – | – | – | – | 20 | – | – |
| Thoracic epidural infusion | – | – | Commenced intraoperatively 0.2% ropivacaine (8 mL/h infusion) → ceased POD 4 | |||||||
| Renal function | ||||||||||
| Urea (mmol/L) | 4.9 | 5.0 | – | – | – | – | 6.7 | 5.4 | 5.1 | 4.1 |
| Creatinine (μmol/L) | 75 | 66 | – | – | – | – | 49 | 44 | 43 | 55 |
| Estimated glomerular filtration rate (mL/min) | 89 | 82 | – | – | – | – | >90 | >90 | >90 | >90 |
| Liver function tests | ||||||||||
| Total bilirubin (μmol/L) | 66 | 7 | – | 8 | 8 | 7 | 6 | |||
| Albumin (g/L) | 38 | 37 | – | 23 | 22 | 24 | 29 | |||
| Alanine aminotransferase (IU/L) | 236 | 19 | – | – | – | – | 29 | 28 | 24 | 20 |
| Aspartate aminotransferase (IU/L) | 98 | 65 | – | – | – | – | 145 | 129 | 112 | 76 |
| Alkaline phosphatase (IU/L) | 551 | 91 | – | – | – | – | 103 | 95 | 93 | 86 |
| Gamma-glutamyl transferase (IU/L) | 1046 | 65 | – | – | – | – | 145 | 129 | 112 | 97 |